Vanda reports Phase III tradipitant trial data in GLP-1-associated vomiting

​

Vanda Pharmaceuticals has reported positive results from the Phase III clinical trial, Study 3601, assessing its Nereus oral therapy to prevent vomiting triggered by GLP-1 receptor agonist treatments.

The post Vanda reports Phase III tradipitant trial data in GLP-1-associated vomiting appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.